Health Trials

Clinical trials

6

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)

the safety and tolerability of different dosages of adsorbed acellular pertussis (two-component) diphtheria-tetanus combined vaccine

Participants needed: 96
Trial details
Phase: Phase 1Age: 10+Biological sex: AllType: InterventionalSponsor: Changchun BCHT Biotechnology Co.Updated: Mar 25, 2026
Eligibility criteria

People aged 10 years or older; [+5]

Axillary body temperature >37.0°C on the day of enrollment of trial participants... [+15]

Read more
Status: Not yet recruiting

A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant)

The goal of this clinical trial is to evaluate the safety and immunogenicity of the influenza virus vaccine (BK-01 adjuvant) in people aged 18 years and older. The main questions it aims to answer is: • Incidence rate of adverse reactions/events after administration Participants will be randomly vaccinated with a single dose of the trial vaccine, control vaccine, adjuvant placebo, or placebo in a 1:1:1:1 ratio. After vaccination, all participants will undergo up to 30-day observation and blood collection.

Participants needed: 160
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Changchun BCHT Biotechnology Co.Updated: Jan 16, 2026
Eligibility criteria

Participants aged 18 years and above; [+4]

Axillary temperature > 37.0℃ on the day of enrollment; [+10]

Read more
Status: Not yet recruiting

Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination

A Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination

Participants needed: 6,680
Trial details
Phase: Phase 3Age: 18-59Biological sex: AllType: InterventionalSponsor: Changchun BCHT Biotechnology Co.Updated: Aug 21, 2025
Eligibility criteria

Healthy participants aged 18-59 years [+2]

Axillary temperature >37.0°C on enrollment day * [+17]

Read more
Status: Recruiting

Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial

The immunogenicity and safety of the adsorption of cell-free diphtheria and tetanus (three-component) combined vaccine were evaluated at 2 months, 4 months and 6 months.

Participants needed: 1,650
Trial details
Phase: Phase 3Age: 2-3Biological sex: AllType: InterventionalSponsor: Changchun BCHT Biotechnology Co.Updated: Aug 8, 2025Locations: 1
Eligibility criteria

Healthy infants and young children who are permanent residents aged 2 months (60... [+2]

History of pertussis, diphtheria, or tetanus; [+18]

Read more
Status: Not yet recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older

To evaluate the immunogenicity 42 days after vaccination with the live attenuated herpes zoster vaccine. To evaluate the safety of the live attenuated herpes zoster vaccine.

Participants needed: 600
Trial details
Phase: Phase 4Age: 40+Biological sex: AllType: InterventionalSponsor: Changchun BCHT Biotechnology Co.Updated: May 8, 2025
Eligibility criteria

Age ≥40 years on enrollment day； [+3]

People who are immune deficient or immunosuppressed due to certain diseases or t... [+10]

Read more
Status: Not yet recruiting

Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials

To evaluate the antibody neutralization activity and safety of rabies mAb CBB 1 combination vaccine used in healthy people

Participants needed: 120
Trial details
Phase: Phase 2Age: 18-50Biological sex: AllType: InterventionalSponsor: Changchun BCHT Biotechnology Co.Updated: Aug 12, 2024Locations: 1
Eligibility criteria

Before the trial, I have had a detailed understanding of the nature, significanc... [+3]

Those who are known to be allergic to the study drug (including excipients, simi... [+27]

Read more